$IKT
Inhibikase Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022025011 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q4
Revenue $63.57K $7.291K $1.940K
YoY Change 3176.8% -97.78% -98.86%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.344M $1.539M $1.653M
YoY Change -18.68% -6.46% 45.01%
% of Gross Profit
Research & Development $3.054M $2.982M $3.390M
YoY Change -9.91% -5.48% 1374.03%
% of Gross Profit
Depreciation & Amortization $5.040K $1.680K
YoY Change
% of Gross Profit
Operating Expenses $4.399M $4.520M $5.043M
YoY Change -12.79% -5.82% 268.13%
Operating Profit -$4.513M
YoY Change 0.94%
Interest Expense $55.92K $0.00 -$160.00
YoY Change -35050.0% -100.0% -98.4%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$4.279M -$4.495M -$5.042M
YoY Change -15.13% 0.52% 316.66%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$4.279M -$4.495M -$5.042M
YoY Change -15.13% 0.52% 316.66%
Net Earnings / Revenue -6731.24% -61645.36% -259877.32%
Basic Earnings Per Share -$0.18
Diluted Earnings Per Share -$0.17 -$0.18 -$199.8K
COMMON SHARES
Basic Shares Outstanding 25.23M 25.23M 25.16M
Diluted Shares Outstanding 25.23M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $23.05M $26.53M $40.75M
YoY Change -43.43% -40.83% 192.12%
Cash & Equivalents $7.190M $5.782M $40.75M
Short-Term Investments $15.86M $20.75M $0.00
Other Short-Term Assets $1.281M $1.438M $1.610M
YoY Change -20.42% 78.51% 93.94%
Inventory
Prepaid Expenses $1.118M $932.4K $107.0K
Receivables $39.88K $13.84K $110.1K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $24.37M $27.99M $42.47M
YoY Change -42.62% -38.99% 187.3%
LONG-TERM ASSETS
Property, Plant & Equipment $236.5K $241.6K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $565.2K $594.8K $0.00
YoY Change 59482300.0%
TOTAL ASSETS
Total Short-Term Assets $24.37M $27.99M $42.47M
Total Long-Term Assets $565.2K $594.8K $0.00
Total Assets $24.94M $28.58M $42.47M
YoY Change -41.28% -37.69% 187.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.151M $781.2K $1.090M
YoY Change 5.63% 41.07% -36.67%
Accrued Expenses $2.398M $2.290M $2.716M
YoY Change -11.68% 20.19% 329.07%
Deferred Revenue $0.00
YoY Change -100.0%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $248.9K
YoY Change 522.28%
Total Short-Term Liabilities $3.695M $3.213M $4.054M
YoY Change -8.85% 18.66% -14.13%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $205.5K $232.0K
YoY Change
Total Long-Term Liabilities $205.5K $232.0K $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.695M $3.213M $4.054M
Total Long-Term Liabilities $205.5K $232.0K $0.00
Total Liabilities $3.901M $3.445M $4.054M
YoY Change -3.79% 27.23% -18.88%
SHAREHOLDERS EQUITY
Retained Earnings -$47.87M -$43.59M -$29.82M
YoY Change 60.55% 75.95% -298.37%
Common Stock $68.80M $68.70M $68.23M
YoY Change 0.83% 1.13% 174.96%
Preferred Stock
YoY Change
Treasury Stock (at cost) $300.4K $314.2K $519.8K
YoY Change -42.21%
Treasury Stock Shares
Shareholders Equity $21.04M $25.14M $38.42M
YoY Change
Total Liabilities & Shareholders Equity $24.94M $28.58M $42.47M
YoY Change -41.28% -37.69% 187.3%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q4
OPERATING ACTIVITIES
Net Income -$4.279M -$4.495M -$5.042M
YoY Change -15.13% 0.52% 316.66%
Depreciation, Depletion And Amortization $5.040K $1.680K
YoY Change
Cash From Operating Activities -$3.556M -$5.505M -$4.096M
YoY Change -13.17% 172.45% 331.14%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$200.2K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $4.963M -$20.73M
YoY Change
Cash From Investing Activities $4.963M -$20.93M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -3.556M -5.505M -4.096M
Cash From Investing Activities 4.963M -20.93M
Cash From Financing Activities 0.000 0.000 0.000
Net Change In Cash 1.407M -26.43M -4.096M
YoY Change -134.34% 1227.76% -129.4%
FREE CASH FLOW
Cash From Operating Activities -$3.556M -$5.505M -$4.096M
Capital Expenditures $0.00 -$200.2K
Free Cash Flow -$3.556M -$5.305M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#GrantMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#GrantMember
CY2022Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#GrantMember
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
CY2021Q4 us-gaap Assets Current
AssetsCurrent
42469999
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
241574
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
353250
CY2022Q3 us-gaap Assets
Assets
28581217
CY2021Q4 us-gaap Assets
Assets
42469999
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
781223
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1089778
CY2022Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
142048
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2289726
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Central Index Key
EntityCentralIndexKey
0001750149
CY2021Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#GrantMember
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39676
dei Entity Registrant Name
EntityRegistrantName
INHIBIKASE THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-3407249
dei Entity Address Address Line1
EntityAddressAddressLine1
3350 Riverwood Parkway SE
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1900
dei Entity Address City Or Town
EntityAddressCityOrTown
Atlanta
dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30339
dei City Area Code
CityAreaCode
678
dei Local Phone Number
LocalPhoneNumber
392-3419
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
IKT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25227051
CY2022Q3 us-gaap Cash
Cash
5781918
CY2021Q4 us-gaap Cash
Cash
40750133
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
20752290
CY2022Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
13842
CY2021Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
110141
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
932419
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
107000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
505924
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1502725
CY2022Q3 us-gaap Assets Current
AssetsCurrent
27986393
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2715761
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4467735
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4471197
CY2022Q3 us-gaap Notes Payable Current
NotesPayableCurrent
0
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
248911
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3212997
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4054450
CY2022Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
232020
CY2022Q3 us-gaap Liabilities
Liabilities
3445017
CY2021Q4 us-gaap Liabilities
Liabilities
4054450
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25227051
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25227051
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25155198
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25155198
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
25227
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
25155
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
68676935
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
68208081
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
26828
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-43592790
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-29817687
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
25136200
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
38415549
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28581217
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42469999
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7291
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
328459
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
59874
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3098661
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7291
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
328459
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
59874
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3098661
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2981653
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-9744444
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3154553
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8980827
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7968846
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1538737
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1644946
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4872681
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4854494
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
4520390
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
4799499
us-gaap Costs And Expenses
CostsAndExpenses
13853508
us-gaap Costs And Expenses
CostsAndExpenses
12823340
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4513099
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4471040
us-gaap Operating Income Loss
OperatingIncomeLoss
-13793634
us-gaap Operating Income Loss
OperatingIncomeLoss
-9724679
CY2022Q3 us-gaap Interest Income Other
InterestIncomeOther
18536
CY2021Q3 us-gaap Interest Income Other
InterestIncomeOther
0
us-gaap Interest Income Other
InterestIncomeOther
18536
us-gaap Interest Income Other
InterestIncomeOther
0
CY2022Q3 us-gaap Interest Expense
InterestExpense
0
CY2021Q3 us-gaap Interest Expense
InterestExpense
157
us-gaap Interest Expense
InterestExpense
5
us-gaap Interest Expense
InterestExpense
19765
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4494563
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-4471197
us-gaap Net Income Loss
NetIncomeLoss
-13775103
us-gaap Net Income Loss
NetIncomeLoss
-9744444
CY2022Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
26828
CY2021Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
26828
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-13748275
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2325741
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13794729
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25227051
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25227051
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25143559
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25143559
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25219931
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25219931
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15868421
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15868421
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
38415549
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
123229
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
67000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
44142
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4640601
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
34009319
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
132767
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4639939
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
29502147
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
101788
CY2022Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
26828
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4494563
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
25136200
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
9784356
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
591124
CY2021Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
237768
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
60391
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2637068
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
8036571
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
322483
CY2021Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
239415
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-43295
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2636179
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
47054352
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
352419
CY2021Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
181762
CY2021Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
44143
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-4471197
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
43161479
us-gaap Net Income Loss
NetIncomeLoss
-13775103
us-gaap Net Income Loss
NetIncomeLoss
-9744444
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10201234
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
20725462
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
ikt Non Cash Consulting Fees
NonCashConsultingFees
67000
ikt Non Cash Consulting Fees
NonCashConsultingFees
60391
us-gaap Depreciation
Depreciation
1681
us-gaap Depreciation
Depreciation
0
us-gaap Share Based Compensation
ShareBasedCompensation
357784
us-gaap Share Based Compensation
ShareBasedCompensation
1266026
ikt Noncash Lease Expense
NoncashLeaseExpense
20818
ikt Noncash Lease Expense
NoncashLeaseExpense
0
ikt Non Cash Ppp Loan Forgiveness
NonCashPPPLoanForgiveness
0
ikt Non Cash Ppp Loan Forgiveness
NonCashPPPLoanForgiveness
27550
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
658945
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-96299
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
217482
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-996801
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
486551
ikt Increase Decrease In Prepaid Research And Development
IncreaseDecreaseInPrepaidResearchAndDevelopment
825419
ikt Increase Decrease In Prepaid Research And Development
IncreaseDecreaseInPrepaidResearchAndDevelopment
-509975
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-308555
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1166879
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-449718
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1272076
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
23683
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
243255
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20968717
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
41135357
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
44142
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
78500
ikt Payment Of Employee Taxes In Connection With Stock Option Exercise
PaymentOfEmployeeTaxesInConnectionWithStockOptionExercise
0
ikt Payment Of Employee Taxes In Connection With Stock Option Exercise
PaymentOfEmployeeTaxesInConnectionWithStockOptionExercise
-77652
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
248911
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
42534
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-204769
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
41093671
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-34968215
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
30892437
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40750133
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13953513
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5781918
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44845950
us-gaap Interest Paid Net
InterestPaidNet
973
us-gaap Interest Paid Net
InterestPaidNet
19608
ikt Ppp Loans Forgiveness
PppLoansForgiveness
0
ikt Ppp Loans Forgiveness
PppLoansForgiveness
27550
us-gaap Nature Of Operations
NatureOfOperations
<div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nature of Business </span></div></div><p style="text-indent:3.733%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inhibikase Therapeutics, Inc. (the “Company,” “we” or “our”) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson’s disease, or PD, and related disorders. The Company's multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases. In 2021, we commenced clinical development of IkT-148009, a small molecule Abelson Tyrosine Kinase inhibitor we believe can modify the course of Parkinson’s disease including its manifestation in the gastrointestinal tract, or GI. The U.S. Food and Drug Administration (“FDA”) review of the Phase 1/1b data and the protocol for the Phase 2a three-month dosing study resulted in the FDA agreeing with the Company’s view that it was appropriate for the Phase 2a study to begin, prompting the Company to initiate the Phase 2 study, the 201 trial, at the end of May 2022. We have opened 16 of 34 selected sites as of November 1, 2022, and 11 patients have randomized into the trial of 120 patients planned to be enrolled, with no serious adverse events observed to date. In October 2022, an Investigational New Drug Application ("IND") to expand use of IkT-148009 into the Parkinson’s-related disease Multiple System Atrophy ("MSA") was filed with the FDA. In November 2022, following review of the IND for IkT-148009 as a treatment for MSA, the FDA notified the Company that it was placing the IkT-148009 programs for Parkinson's disease and MSA on clinical hold. The FDA indicated it will provide an official clinical hold letter to Inhibikase within 30 days to explain the basis of this decision.</span></p><p style="text-indent:3.733%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is also developing platform technologies for alternate ways to deliver protein kinase inhibitors in patients. Our first example of this technology is IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat Stable phase Chronic Myelogenous Leukemia ("SP CML"). Pursuant to its IND which was cleared by the FDA in August 2022, IkT-001Pro will be evaluated in a two-part dose finding/dose equivalence study in up to 56 healthy volunteers. The study is designed to evaluate the steady-state pharmacokinetics of IkT-001Pro and determine the dose of IkT-001Pro equivalent to 400 mg imatinib mesylate, the standard-of-care dose for SP-CML. Following the study, Inhibikase will confer with the FDA and seek agreement on the requirements for the New Drug Application ("NDA") process following the proposed approval path for IkT-001Pro under the 505(b)(2) statute. The Company will simultaneously pursue a superiority study comparing the selected does of IkT-001Pro to standard-of-care 400 mg imatinib mesylate in SP-CML patients using a novel, two-period-wait-list-crossover-switching study.</span></p>
CY2022Q3 ikt Working Capital
WorkingCapital
24773396
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-43592790
CY2022Q3 us-gaap Cash
Cash
5781918
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
20752290
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3070949
CY2022Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
385888
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
300386
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.733%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the Company’s financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company utilizes certain estimates in the determination of its assertions made in connection with its assessment of liquidity and working capital adequacy, of the fair value of its stock options and warrants, deferred tax valuation allowances and revenue recognition, to record expenses relating to research and development contracts and accrued expenses. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from such estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.733%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the three and nine months ended September 30, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company derived more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of its total revenue from a single source, the United States Government, in the form of federal research grants.</span></p>
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
20725462
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
50836
us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
24008
CY2022Q3 us-gaap Marketable Securities
MarketableSecurities
20752290
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
243255
CY2022Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
1681
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
241574
CY2022Q3 ikt Accrued Consulting Current
AccruedConsultingCurrent
229661
CY2021Q4 ikt Accrued Consulting Current
AccruedConsultingCurrent
210000
CY2022Q3 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
417573
CY2021Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
421734
CY2022Q3 us-gaap Deferred Revenue
DeferredRevenue
23683
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
0
CY2022Q3 ikt Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
1586138
CY2021Q4 ikt Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
2077932
CY2022Q3 ikt Accrued Interest Current
AccruedInterestCurrent
0
CY2021Q4 ikt Accrued Interest Current
AccruedInterestCurrent
968
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
32671
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5127
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2289726
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2715761
CY2022Q3 us-gaap Notes Payable Current
NotesPayableCurrent
0
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
248911
CY2020Q1 us-gaap Debt Instrument Issuance Date1
DebtInstrumentIssuanceDate1
2020-02-05
CY2020Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0159
CY2020Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.87
ikt Common Stock Per Share Entitled To Vote
CommonStockPerShareEntitledToVote
1
CY2022Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5589991
CY2022Q1 ikt Common Stock In Connection With Exercise Of Non Qualified Stock Options Shares
CommonStockInConnectionWithExerciseOfNonQualifiedStockOptionsShares
21853
CY2022Q1 us-gaap Stock Option Exercise Price Increase
StockOptionExercisePriceIncrease
2.02
CY2022Q1 ikt Additional Rights Or Options Granted
AdditionalRightsOrOptionsGranted
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
160000
CY2022Q3 us-gaap Stock Issued During Period Shares Restricted Stock Award Forfeited
StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
40000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
239887
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
68628
CY2021Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
6.82
CY2021Q2 ikt Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue
259674
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
357784
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1266026
us-gaap Net Income Loss
NetIncomeLoss
-13775103
us-gaap Net Income Loss
NetIncomeLoss
-9744444
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25219931
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25219931
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15868421
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15868421
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5589991
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5191957
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
374068
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
142048
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
232020
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
20818
us-gaap Operating Lease Expense
OperatingLeaseExpense
20818
CY2022Q3 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
33469
CY2022Q3 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
145836
CY2022Q3 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
150095
CY2022Q3 us-gaap Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
114966
CY2022Q3 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
444366
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
70298
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
374068
CY2022Q3 us-gaap Subsequent Event Description
SubsequentEventDescription
On July 25, 2022, the Company received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market (the “Minimum Bid Price Requirement”), as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Notice”).
CY2022Q3 ikt Closing Price Of Common Stock
ClosingPriceOfCommonStock
1.00
us-gaap Subsequent Event Description
SubsequentEventDescription
The Company is provided a compliance period of 180 calendar days from the date of the Minimum Bid Price Notice, or until January 23, 2023, to regain compliance with the Minimum Bid Price Requirement, pursuant to Nasdaq Listing Rule 5810(c)(3)(A) (the “Minimum Bid Price Compliance Period”). If at any time before January 23, 2023 the closing bid price of the Company’s Common Stock closes at or above $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the Minimum Bid Price Requirement, and the matter would be resolved.
CY2022Q3 ikt Closing Price Of Common Stock
ClosingPriceOfCommonStock
1.00

Files In Submission

Name View Source Status
0000950170-22-025011-index-headers.html Edgar Link pending
0000950170-22-025011-index.html Edgar Link pending
0000950170-22-025011.txt Edgar Link pending
0000950170-22-025011-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ikt-20220930.htm Edgar Link pending
ikt-20220930.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ikt-20220930_cal.xml Edgar Link unprocessable
ikt-ex31_1.htm Edgar Link pending
ikt-ex31_2.htm Edgar Link pending
ikt-ex32_1.htm Edgar Link pending
ikt-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
ikt-20220930_htm.xml Edgar Link completed
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ikt-20220930_lab.xml Edgar Link unprocessable
ikt-20220930_pre.xml Edgar Link unprocessable
ikt-20220930_def.xml Edgar Link unprocessable